Citius Oncology, Inc. (CTOR)

NASDAQ: CTOR · USD

$0.55

-0.04 (-7.4%)· Recorded snapshot

Market cap	58.2M
Revenue (ttm)	7.1M
Net income (ttm)	-46.1M
EPS (ttm)	-$0.49
Shares out	105.8M
Volume	188,285.328
Beta	3.57

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 7.1M
Net income (ttm): -46.1M
EPS (ttm): -$0.49
Market cap: 58.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-126.6

P25 -113.8P50 -46.5P75 -0.9

ROIC-68.4

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All CTOR indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001851484
Company name	Citius Oncology, Inc.
Country	United States
Country code	US
CUSIP number	17331Y109
Earnings date	2026-12-22
Earnings time	amc
Enterprise value	$51.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	September
Founded	2021
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
Is SPAC	No
ISIN number	US17331Y1091
Last 10-K release date	2025-12-23
Last earnings date	2026-08-14
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$58.2M
Market cap category	Micro-Cap
Next earnings date	2026-12-22
Options	No
Price	$0.55
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-03
Symbol	CTOR
U.S. state	New Jersey
Website	https://citiusonc.com/overview/default.aspx

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-89.66%
EV/Sales	7.29x
FCF / EV yield	-37.42%
FCF yield	-33.33%
Forward EV/Sales	0.75x
Forward P/S	0.84x
Industry forward P/E	14.04x
Industry P/E	107.82x
P/B ratio	1.44x
P/S ratio	8.19x
Price / tangible book value	1.44x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	74.82%
Operating margin	-668.15%
Pretax margin	-645.64%
ROA	-29.12%
ROCE	-89.06%
ROE	-126.58%
ROIC	-68.37%
SBC / revenue	187.77%
Tax / revenue	2.67%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth (QoQ)	-10.41%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-47.5M
EPS	$-0.49
FCF per share	$-0.18
Financing cash flow	$48.7M
Free cash flow	$-19.4M
Free cash flow minus SBC	$-32.7M
Gross profit	$5.3M
Income taxes	$189,923
Investing cash flow	$-12.8M
Net borrowing	$9.6M
Net cash flow	$16.6M
Net income	$-46.1M
Operating cash flow minus SBC	$-32.7M
Operating income	$-47.5M
Revenue	$7.1M
Stock-based compensation	$13.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-1.88
Book value per share	$0.38
Debt / equity	0.25
Interest coverage	-129.05
Long-term assets	$69.4M
Long-term liabilities	$12.9M
Net cash (debt)	$6.4M
Net cash / market cap	10.92%
Net debt / equity	-0.16
Piotroski F-Score	2
Shareholders' equity	$40.4M
Tangible book value	$40.4M
Tangible book value per share	$0.38
Total assets	$112.1M
Total cash	$16.6M
Total debt	$10.2M
Total liabilities	$71.7M
WACC	20.76%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.07
Current assets	$42.7M
Current liabilities	$58.8M
Current ratio	0.73
Inventory turnover	0.09
Net working capital	$-32.6M
Quick ratio	0.29
Working capital	$-16.1M
Working capital turnover	-0.28

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-31.4%
Dividend yield	0%
Shareholder yield	-31.4%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$0.78
1D price change	-7.42%
1M price change	-42.11%
1M total return	-42.11%
1W price change	-9.98%
1W total return	-9.98%
1Y price change	-68.57%
1Y return CAGR	-68.6%
1Y total return	-68.57%
20-day SMA	$0.69
200-day SMA	$0.83
3M price change	-7.14%
3M total return	-7.14%
3Y price change	-94.95%
3Y return CAGR	-63.04%
3Y total return	-94.95%
50-day SMA	$0.83
50-day SMA vs 200-day SMA	50under200
52-week high	$1.83
52-week high date	2025-12-01
52-week low	$0.49
52-week low date	2026-03-30
6M price change	-41.79%
6M total return	-41.79%
After-hours change	1%
After-hours close	$0.55
After-hours price	$0.56
All-time high	$49.00
All-time high date	2024-08-06
All-time low	$0.49
All-time low date	2026-03-30
Average true range (ATR)	$0.09
Average volume	144.4K
Beta (1Y)	4.62
Beta (2Y)	2.87
Beta (5Y)	3.57
Change from 52-week high	-69.95%
Change from 52-week low	11.97%
Change from all-time high	-98.88%
Change from all-time low	11.97%
Change from open	-9.57%
Day's gap	2.37%
Dollar volume	$103,557
High price	$0.62
Low price	$0.55
Monthly RSI	32.59
Open price	$0.61
Position in 52-week range	4.28%
Premarket change	2.82%
Premarket close	$0.55
Premarket price	$0.57
Premarket volume	200
Previous close	$0.59
Price vs 150-day SMA	-29.45%
Price vs 20-day SMA	-20.29%
Price vs 200-day SMA	-33.74%
Price vs 50-day SMA	-33.7%
Relative volume	1.3
RSI	32.35
Sharpe ratio	-0.8
Sharpe ratio (3Y)	0.21
Sortino ratio	-1.1
Sortino ratio (3Y)	0.45
Volume	188.3K
Weekly RSI	39.15
YTD price change	-45%
YTD total return	-45%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	31M
Float percentage	29.3%
Shares change (QoQ)	7.86%
Shares change (YoY)	31.4%
Shares held by insiders	0.02%
Shares held by institutions	5.2%
Shares outstanding	105.8M
Short % of float	0.73%
Short % of shares	0.22%
Short ratio	2.1 days

Deeper analysis on CTOR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CTOR report

Is a complete CTOR research report available?

No complete published report is available for Citius Oncology, Inc. (CTOR) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Citius Oncology, Inc. (CTOR)

Price

Financial snapshot

Fair-value bridge

Latest news · CTOR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CTOR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CTOR

Frequently asked questions